Home LiteratureArticle Details
PMID: 10638988 Published · ppublish English Journal Article

Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer.

British journal of cancer ·Vol. 82 ·No. 1 ·2000-01-00 ·Pages 186-94

Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ, Habib FK

Abstract

Earlier studies have demonstrated an unexplained depletion of the epidermal growth factor receptor (EGFR) protein expression in prostatic cancer. We now attribute this phenomenon to the presence of a variant EGFR (EGFRvIII) that is highly expressed in malignant prostatic neoplasms. In a retrospective study, normal, benign hyperplastic and malignant prostatic tissues were examined at the mRNA and protein levels for the presence of this mutant receptor. The results demonstrated that whilst EGFRvIII was not present in normal prostatic glands, the level of expression of this variant protein increased progressively with the gradual transformation of the tissues to the malignant phenotype. The selective association of high EGFRvIII levels with the cancer phenotype underlines the role that this mutant receptor may maintain in the initiation and progression of malignant prostatic growth, and opens the way for new approaches in the management of this disease including gene therapy.

MeSH Terms
Analysis of Variance Blotting, Western Drug Resistance, Neoplasm ErbB Receptors/analysis Humans Male Neoplasm Proteins/analysis Phenotype Prostatic Neoplasms/chemistry RNA, Messenger/analysis Retrospective Studies Reverse Transcriptase Polymerase Chain Reaction
Chemicals
Neoplasm Proteins RNA, Messenger ErbB Receptors
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Olapade-Olaopa E O
Department of Urology, Leicester General Hospital, UK.
Moscatello D K
MacKay E H
Horsburgh T
Sandhu D P
Terry T R
Wong A J
Habib F K
References (46)
46 references, click to expand
  1. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  2. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma.
    Clin Cancer Res. 1999 Mar;5(3):569-76 PMID: 10100708
  3. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.
    Nature. 1984 May 31-Jun 6;309(5967):418-25 PMID: 6328312
  4. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines.
    Proc Natl Acad Sci U S A. 1984 Dec;81(23):7308-12 PMID: 6095284
  5. Hyperproduction and gene amplification of the epidermal growth factor receptor in squamous cell carcinomas.
    Jpn J Cancer Res. 1985 Aug;76(8):663-6 PMID: 2995289
  6. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas.
    J Pathol. 1986 May;149(1):9-14 PMID: 2425067
  7. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.
    Cancer Res. 1987 Feb 1;47(3):707-12 PMID: 3467839
  8. Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods.
    J Endocrinol. 1987 Apr;113(1):147-53 PMID: 2438365
  9. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
    Lancet. 1987 Jun 20;1(8547):1398-402 PMID: 2884496
  10. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.
    Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 PMID: 3477813
  11. The EGF receptor: structure, regulation and potential role in malignancy.
    Cancer Surv. 1985;4(4):767-88 PMID: 2824044
  12. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma.
    Cancer Res. 1988 Jan 1;48(1):161-4 PMID: 3334990
  13. Growth factor receptors and oncogene expression in prostate cells.
    Am J Clin Oncol. 1988;11 Suppl 2:S1-7 PMID: 2468269
  14. Growth factors as novel therapeutic targets in neoplastic disease.
    Cancer Surv. 1988;7(4):653-74 PMID: 3072070
  15. Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumour.
    Br J Cancer. 1989 Jul;60(1):41-4 PMID: 2478180
  16. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines.
    J Urol. 1990 Jun;143(6):1272-4 PMID: 1692888
  17. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.
    Proc Natl Acad Sci U S A. 1990 Jun;87(11):4207-11 PMID: 1693434
  18. Growth factors in development, transformation, and tumorigenesis.
    Cell. 1991 Jan 25;64(2):271-80 PMID: 1988148
  19. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.
    J Urol. 1992 Feb;147(2):496-9 PMID: 1370701
  20. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia.
    Arch Pathol Lab Med. 1992 Mar;116(3):269-73 PMID: 1371380
  21. Structural alterations of the epidermal growth factor receptor gene in human gliomas.
    Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 PMID: 1557402
  22. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.
    Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 PMID: 1584765
  23. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha.
    Cancer Res. 1992 Nov 1;52(21):5887-92 PMID: 1394216
  24. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
    Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31 PMID: 8052651
  25. Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue.
    Prostate. 1994 Oct;25(4):199-205 PMID: 7521960
  26. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues.
    J Urol. 1994 Dec;152(6 Pt 1):2120-4 PMID: 7525998
  27. Characterization of a novel epidermal-growth-factor-receptor-related 200-kDa tyrosine kinase in tumor cells.
    Eur J Biochem. 1995 Jun 15;230(3):951-7 PMID: 7601158
  28. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Cancer Res. 1995 Jul 15;55(14):3140-8 PMID: 7606735
  29. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.
    Cancer Res. 1995 Dec 1;55(23):5536-9 PMID: 7585629
  30. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
    Br J Cancer. 1996 Jan;73(2):228-35 PMID: 8546911
  31. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.
    Br J Cancer. 1996 Feb;73(3):301-6 PMID: 8562334
  32. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.
    Oncogene. 1996 Jul 4;13(1):85-96 PMID: 8700557
  33. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue.
    Hum Pathol. 1996 Jul;27(7):688-94 PMID: 8698313
  34. Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes. Implications for glial oncogenesis.
    Cancer. 1996 Sep 15;78(6):1272-83 PMID: 8826951
  35. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.
    Cancer Res. 1996 Nov 1;56(21):5079-86 PMID: 8895767
  36. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors.
    Cancer Res. 1997 Apr 15;57(8):1419-24 PMID: 9108438
  37. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.
    J Urol. 1997 Jul;158(1):12-22 PMID: 9186314
  38. Prostate cancer: indicators of aggressiveness.
    Eur Urol. 1997;32 Suppl 3:15-23 PMID: 9267782
  39. Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin.
    Int J Cancer. 1998 Mar 16;75(6):878-84 PMID: 9506533
  40. Type I growth factor receptors: current status and future work.
    Biochem Soc Symp. 1998;63:193-8 PMID: 9513723
  41. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.
    Br J Cancer. 1998 Mar;77(6):855-61 PMID: 9528825
  42. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
    Cancer. 1998 Jun 1;82(11):2256-61 PMID: 9610707
  43. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
    Cancer Res. 1999 Jan 1;59(1):227-33 PMID: 9892211
  44. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Clin Cancer Res. 1997 Sep;3(9):1643-51 PMID: 9815855
  45. Variability of immunohistochemical reactivity on stored paraffin slides.
    J Clin Pathol. 1998 Dec;51(12):943 PMID: 10070342
  46. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.
    J Urol. 1974 Jan;111(1):58-64 PMID: 4813554
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1054/bjoc.1999.0898
Published
2000-01-00
Pages
186-94
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2363203
Subset
IM
External Links
PubMed source DOI: 10.1054/bjoc.1999.0898 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2